Dear All, I’ve written in the past about the creative work done by the Milken Institute on health care financing (26 Mar 2022 newsletter, “Pull mechanisms: Private capital can multiply Subscription (Netflix) and TEV models!”). Milken recently held a 3-day symposium entitled “The Future of Health Summit” (4-6 Nov 2025) during which there was an
This newsletter is part of a series — here are the links to Part 1, Part 2, (this one is Part 3), Part 4, and Part 5. Dear All, As a coda to the two newsletters on Chemicals, Drugs, and Halicin (link and link), XKCD gets the final word: Image reproduced with permission from https://xkcd.com/1217/. And, you might
Dear All, I wrote in the 4 Oct 2025 newsletter about WHO’s updated reviews of antibacterial therapeutics and diagnostics. Team WHO have now released dashboard versions of the reports: Preclinical pipeline dashboard Clinical pipeline dashboard Underlying .xlsx dataset And for reference, don’t forget that you can find a comparative summary of the priority pathogen lists on this
Dear All, When I wrote earlier this year (23 Jan 2025 newsletter) that the January 2025 PACCARB meeting (Presidential Advisory Council on Combatting Antimicrobial Resistant Bacteria) had been cancelled, we had all hoped this would be a transient adjustment and that the very important work of PACCARB would resume in due course. Unfortunately, this has
Dear All (and with thanks to Frédéric Peyrane for leading on this newsletter): You will know that we eagerly watching the work in the EU on implementing a set of pull incentives based on use of ‘transferable data exclusivity voucher’ (TEV), also referred to as a ‘transferable exclusivity extension voucher’ (TEEV). In brief, the concept is that a TEEV
Dear All (unapologetically wonkish … very important material!), Let’s set the scene today by considering two quotes: Prosaic: “The successful treatment of patients with cancer has long depended on the capacity to manage infectious complications.” (Shropshire 2025, cited below) Blunt translation: “Your cancer will be controlled, but then you may die of infection.” (Abdul Ghafur,
Dear All, Earlier this year (20 Apr 2025 newsletter), Vivli announced their 2025 AMR Surveillance Data Challenge. Funded by Johnson & Johnson, Paratek, Pfizer and a National Institutes of Health (NIH) award1 the goal of this challenge is to produce new insights using existing industry AMR surveillance data. This is the third challenge issued by Vivli,
Dear All, PACE (Pathways to Antimicrobial Clinical Efficacy), a large UK-based public-private funder, have announced a £6 million funding round for projects in the hit-to-lead and lead optimization stages. The call is for antibacterial projects that target WHO priority Gram-negative pathogens (Enterobacteriaceae, A. baumannii and P. aeruginosa; see the AMR.Solutions summary of the priority pathogen
Dear All, The EU have today announced the European Partnership on One Health AMR (OHAMR), a major AMR funding initiative that will run for 10 years (press release, webpage)! As a bit of background, the EU have invested more than EUR 1 billion in hundreds of AMR-focused projects over the past ~15 years. From my
Dear All, I am pleased to learn that BARDA is holding a one-day innovation symposium on 20 Nov 2025. As you know, BARDA is a consistently creative funder of diverse medical countermeasures, including new antibiotics. For background, see these prior newsletters: 22 Jul 2025 newsletter: “BARDA RFP: Antibiotic for HABP/VABP or Bloodstream Infection” 5 Nov